AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH.
Atacand is a prescription medicine, a selective, AT1 subtype angiotensin II receptor antagonist blocker (ARB) that is indicated for the treatment of hypertension and heart failure. Atacand is also available in Europe as a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide (Atacand Plus). Atacand is indicated for the management of hypertension in adults and children/adolescents, as well as heart failure in adults. Atacand Plus is indicated for the management of hypertension when monotherapy is not sufficiently effective. Atacand was developed in collaboration with Takeda. Each company holds the exclusive rights to the product in certain markets.
The agreement is expected to complete in the third quarter of 2018. AstraZeneca will continue to manufacture and supply Atacand and Atacand Plus under a supply agreement and will continue to commercialise the medicines in all markets where it still holds the rights. Cheplapharm will pay AstraZeneca $200 million on completion of the agreement, plus a time-bound payment of $10 million and sales-contingent milestones.
Cheplapharm Arzneimittel GmbH was founded in 1998 and is based in Mesekenhagen, Germany. Cheplapharm, a family owned biotech, focuses on the acquisition of drug licenses with expired patent protection and no generics competition. These drugs have become too small to remain relevant for the big pharmaceuticals companies, but are still highly attractive for Cheplapharm as a new owner. In the past 10 years, Cheplapharm has built a diversified portfolio consisting of drugs covering a wide array of indications. Production and distribution of the drugs are outsourced. An in-house medicinal department ensures flawless product quality as well as full compliance with all applicable regulation.